| First author, year . | Country . | Study design . | Sample size . | Cardiac amyloidosis excluded . | AS definition . | LF-LG AS n (%) . | Primary outcome . | Secondary outcome (Y/N) . | AVR (%) . | |
|---|---|---|---|---|---|---|---|---|---|---|
| All-cause mortality . | HF hospitalization . | |||||||||
| Hammer M, 202115 | Asia (Israel) | Prospective single centre | 57 | No | AHA/ESC guidelines | NA | HF hospitalization + stroke | No | Yes | TAVR (88%), SAVR (12%) |
| Tamarappoo B, 202020 | America (USA) | Retrospective single centre | 150 | No | AHA/ESC guidelines | 150 (100%) | HF hospitalization + all-cause mortality | No | No | TAVR (100%) |
| Han D, 202121 | America (USA) | Retrospective single centre | 109 | No | AHA/ESC guidelines | NA | LVEF recovery (absolute increase of LVEF ≥ 10%) | No | No | TAVR (100%) |
| Suzuki M, 202122 | Asia (Japan) | Retrospective single centre | 95 | No | AHA/ESC guidelines | 9 (9%) | HF hospitalization + all-cause mortality | Yes | Yes | TAVR (78%), SAVR (22%) |
| Scully PR, 202223 | Europe (UK) | Retrospective single centre | 106 | Yes | AHA/ESC guidelines | NA | All-cause mortality | Yes | No | TAVR (100%) |
| Ishiyama M, 202324 | Asia (Japan) | Retrospective single centre | 71 | No | AHA/ESC guidelines | 14 (19.7%) | HF hospitalization + all-cause mortality | Yes | Yes | TAVR (100%) |
| Vignale D, 202325 | Europe (Italy) | Prospective single centre | 113 | No | AHA/ESC guidelines | 15 (13%) | HF hospitalization + all-cause mortality | Yes | Yes | TAVR (100%) |
| Koike H, 202426 | America (USA) | Retrospective single centre | 300 | No (1 patient excluded for prior history of CA) | AHA/ESC guidelines | NA | HF hospitalization + all-cause mortality | Yes | No | TAVR (100%) |
| Takahashi M, 202427 | Asia (Japan) | Retrospective single centre | 127 | No | AHA/ESC guidelines | 6 (5%) | HF hospitalization + all-cause mortality | No | No | TAVR (100%) |
| Patel KP, 202428 | Europe (UK) | Prospective single centre | 95 | Yes | AHA/ESC guidelines | NA | All-cause mortality | Yes | No | TAVR (100%) |
| First author, year . | Country . | Study design . | Sample size . | Cardiac amyloidosis excluded . | AS definition . | LF-LG AS n (%) . | Primary outcome . | Secondary outcome (Y/N) . | AVR (%) . | |
|---|---|---|---|---|---|---|---|---|---|---|
| All-cause mortality . | HF hospitalization . | |||||||||
| Hammer M, 202115 | Asia (Israel) | Prospective single centre | 57 | No | AHA/ESC guidelines | NA | HF hospitalization + stroke | No | Yes | TAVR (88%), SAVR (12%) |
| Tamarappoo B, 202020 | America (USA) | Retrospective single centre | 150 | No | AHA/ESC guidelines | 150 (100%) | HF hospitalization + all-cause mortality | No | No | TAVR (100%) |
| Han D, 202121 | America (USA) | Retrospective single centre | 109 | No | AHA/ESC guidelines | NA | LVEF recovery (absolute increase of LVEF ≥ 10%) | No | No | TAVR (100%) |
| Suzuki M, 202122 | Asia (Japan) | Retrospective single centre | 95 | No | AHA/ESC guidelines | 9 (9%) | HF hospitalization + all-cause mortality | Yes | Yes | TAVR (78%), SAVR (22%) |
| Scully PR, 202223 | Europe (UK) | Retrospective single centre | 106 | Yes | AHA/ESC guidelines | NA | All-cause mortality | Yes | No | TAVR (100%) |
| Ishiyama M, 202324 | Asia (Japan) | Retrospective single centre | 71 | No | AHA/ESC guidelines | 14 (19.7%) | HF hospitalization + all-cause mortality | Yes | Yes | TAVR (100%) |
| Vignale D, 202325 | Europe (Italy) | Prospective single centre | 113 | No | AHA/ESC guidelines | 15 (13%) | HF hospitalization + all-cause mortality | Yes | Yes | TAVR (100%) |
| Koike H, 202426 | America (USA) | Retrospective single centre | 300 | No (1 patient excluded for prior history of CA) | AHA/ESC guidelines | NA | HF hospitalization + all-cause mortality | Yes | No | TAVR (100%) |
| Takahashi M, 202427 | Asia (Japan) | Retrospective single centre | 127 | No | AHA/ESC guidelines | 6 (5%) | HF hospitalization + all-cause mortality | No | No | TAVR (100%) |
| Patel KP, 202428 | Europe (UK) | Prospective single centre | 95 | Yes | AHA/ESC guidelines | NA | All-cause mortality | Yes | No | TAVR (100%) |
LF-LG, low flow, low gradient; AS, aortic stenosis; AVR, aortic valve replacement; HF, heart failure; ASE, American Society of Echocardiography; ESC, European Society of Cardiology; TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement; LVEF, left ventricular ejection fraction; CA, cardiac amyloidosis; NA, not available.
| First author, year . | Country . | Study design . | Sample size . | Cardiac amyloidosis excluded . | AS definition . | LF-LG AS n (%) . | Primary outcome . | Secondary outcome (Y/N) . | AVR (%) . | |
|---|---|---|---|---|---|---|---|---|---|---|
| All-cause mortality . | HF hospitalization . | |||||||||
| Hammer M, 202115 | Asia (Israel) | Prospective single centre | 57 | No | AHA/ESC guidelines | NA | HF hospitalization + stroke | No | Yes | TAVR (88%), SAVR (12%) |
| Tamarappoo B, 202020 | America (USA) | Retrospective single centre | 150 | No | AHA/ESC guidelines | 150 (100%) | HF hospitalization + all-cause mortality | No | No | TAVR (100%) |
| Han D, 202121 | America (USA) | Retrospective single centre | 109 | No | AHA/ESC guidelines | NA | LVEF recovery (absolute increase of LVEF ≥ 10%) | No | No | TAVR (100%) |
| Suzuki M, 202122 | Asia (Japan) | Retrospective single centre | 95 | No | AHA/ESC guidelines | 9 (9%) | HF hospitalization + all-cause mortality | Yes | Yes | TAVR (78%), SAVR (22%) |
| Scully PR, 202223 | Europe (UK) | Retrospective single centre | 106 | Yes | AHA/ESC guidelines | NA | All-cause mortality | Yes | No | TAVR (100%) |
| Ishiyama M, 202324 | Asia (Japan) | Retrospective single centre | 71 | No | AHA/ESC guidelines | 14 (19.7%) | HF hospitalization + all-cause mortality | Yes | Yes | TAVR (100%) |
| Vignale D, 202325 | Europe (Italy) | Prospective single centre | 113 | No | AHA/ESC guidelines | 15 (13%) | HF hospitalization + all-cause mortality | Yes | Yes | TAVR (100%) |
| Koike H, 202426 | America (USA) | Retrospective single centre | 300 | No (1 patient excluded for prior history of CA) | AHA/ESC guidelines | NA | HF hospitalization + all-cause mortality | Yes | No | TAVR (100%) |
| Takahashi M, 202427 | Asia (Japan) | Retrospective single centre | 127 | No | AHA/ESC guidelines | 6 (5%) | HF hospitalization + all-cause mortality | No | No | TAVR (100%) |
| Patel KP, 202428 | Europe (UK) | Prospective single centre | 95 | Yes | AHA/ESC guidelines | NA | All-cause mortality | Yes | No | TAVR (100%) |
| First author, year . | Country . | Study design . | Sample size . | Cardiac amyloidosis excluded . | AS definition . | LF-LG AS n (%) . | Primary outcome . | Secondary outcome (Y/N) . | AVR (%) . | |
|---|---|---|---|---|---|---|---|---|---|---|
| All-cause mortality . | HF hospitalization . | |||||||||
| Hammer M, 202115 | Asia (Israel) | Prospective single centre | 57 | No | AHA/ESC guidelines | NA | HF hospitalization + stroke | No | Yes | TAVR (88%), SAVR (12%) |
| Tamarappoo B, 202020 | America (USA) | Retrospective single centre | 150 | No | AHA/ESC guidelines | 150 (100%) | HF hospitalization + all-cause mortality | No | No | TAVR (100%) |
| Han D, 202121 | America (USA) | Retrospective single centre | 109 | No | AHA/ESC guidelines | NA | LVEF recovery (absolute increase of LVEF ≥ 10%) | No | No | TAVR (100%) |
| Suzuki M, 202122 | Asia (Japan) | Retrospective single centre | 95 | No | AHA/ESC guidelines | 9 (9%) | HF hospitalization + all-cause mortality | Yes | Yes | TAVR (78%), SAVR (22%) |
| Scully PR, 202223 | Europe (UK) | Retrospective single centre | 106 | Yes | AHA/ESC guidelines | NA | All-cause mortality | Yes | No | TAVR (100%) |
| Ishiyama M, 202324 | Asia (Japan) | Retrospective single centre | 71 | No | AHA/ESC guidelines | 14 (19.7%) | HF hospitalization + all-cause mortality | Yes | Yes | TAVR (100%) |
| Vignale D, 202325 | Europe (Italy) | Prospective single centre | 113 | No | AHA/ESC guidelines | 15 (13%) | HF hospitalization + all-cause mortality | Yes | Yes | TAVR (100%) |
| Koike H, 202426 | America (USA) | Retrospective single centre | 300 | No (1 patient excluded for prior history of CA) | AHA/ESC guidelines | NA | HF hospitalization + all-cause mortality | Yes | No | TAVR (100%) |
| Takahashi M, 202427 | Asia (Japan) | Retrospective single centre | 127 | No | AHA/ESC guidelines | 6 (5%) | HF hospitalization + all-cause mortality | No | No | TAVR (100%) |
| Patel KP, 202428 | Europe (UK) | Prospective single centre | 95 | Yes | AHA/ESC guidelines | NA | All-cause mortality | Yes | No | TAVR (100%) |
LF-LG, low flow, low gradient; AS, aortic stenosis; AVR, aortic valve replacement; HF, heart failure; ASE, American Society of Echocardiography; ESC, European Society of Cardiology; TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement; LVEF, left ventricular ejection fraction; CA, cardiac amyloidosis; NA, not available.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
